Covid-19. COVID-19, virus identified
Conditions
Interventions
Intervention 1: Antioxidant supplement,Antioxidant supplement, this study is a clinical trial study. Initially, capsules containing defined doses of antioxidant compounds are formulated with the formu
Sponsors
Qazvin University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: A positive PCR test for a new coronavirus Having an involvement in a CT scan of the lungs and a definitive diagnosis by the treating physician that the person is infected Therefore, people whose confirmed results of this virus are confirmed and who have 2 or more of the following symptoms will be studied in the following study: Including: Patients with pulmonary involvement of 50% and above (severe cases) (sometimes closed At the discretion of the physician and the patient's condition, lower lung involvement is also a criterion for hospitalization (moderate cases), 90 <O2 saturation <94 (moderate to severe cases) and o2 saturation <90 (severe cases), sub-cough symptoms (visual assessment criteria) Sore throat (patient report), headache (patient report), nasal congestion (patient report), fever (temperature above 37.3), body aches and pains (patient report), fatigue (patient report)
Exclusion criteria
Exclusion criteria: Patients suspected of having a bacterial respiratory infection at the beginning of the study Patients with serious chronic diseases. Pregnant women Patients with HIV Patients with cancer Patients with vascular disease Patient with endocrine disease Patients who become infected during studying
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Cough. Timepoint: At the beginning of the study, 14 and 28 days. Method of measurement: frequency and severity.;Chest pain. Timepoint: At the beginning of the study, 14 days. Method of measurement: presence or absence.;Shortness of breath. Timepoint: At the beginning of the study, 14 days. Method of measurement: presence or absence.;O2 saturation level. Timepoint: At the beginning of the study, 14 days. Method of measurement: Oxygen level (O2 Saturation) with device.;Number of days with tachypnea. Timepoint: At the beginning of the study, 14 days. Method of measurement: Breathe more than 12-20 times a minute.;Fever. Timepoint: At the beginning of the study, 14 days. Method of measurement: Temperatures above 37.3, with an accuracy of 6 hours.;Fibrinogen levels. Timepoint: At the beginning of the study, 14 days. Method of measurement: Diagnostic laboratory.;Di-dimer. Timepoint: At the beginning of the study, 14 days. Method of measurement: Diagnostic laboratory.;ROS. Timepoint: At the beginning of the study, 14 days. Method of measurement: Diagnostic laboratory.;Laboratory indicators. Timepoint: At the beginning of the study, 14 days. Method of measurement: Diagnostic laboratory.;Duration of possible need for use of mechanical lung ventilation systems. Timepoint: At the beginning of the study, 14 days. Method of measurement: Duration of possible need for use of mechanical lung ventilation systems.;Survival rate of patients. Timepoint: At the beginning of the study, 14 and 28 days. Method of measurement: Duration of clearance and mortality 28 days. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactDr Ehsan Aali
Qazvin University of Medical Sciences
Outcome results
None listed